IN2015DN03984A - - Google Patents

Info

Publication number
IN2015DN03984A
IN2015DN03984A IN3984DEN2015A IN2015DN03984A IN 2015DN03984 A IN2015DN03984 A IN 2015DN03984A IN 3984DEN2015 A IN3984DEN2015 A IN 3984DEN2015A IN 2015DN03984 A IN2015DN03984 A IN 2015DN03984A
Authority
IN
India
Prior art keywords
active ingredient
controlled release
pharmaceutical compositions
dosage form
subject invention
Prior art date
Application number
Other languages
English (en)
Inventor
Varinder Ahuja
Rajan Verma
Umesh Vinayakrao Barabde
Arne Hagsten
Kristin Wannerberger
Rambabu Boorugu
Amol Vilasrao Somwanshi
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to IN3984DEN2015 priority Critical patent/IN2015DN03984A/en
Publication of IN2015DN03984A publication Critical patent/IN2015DN03984A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN3984DEN2015 2012-11-21 2013-11-21 IN2015DN03984A (he)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN3984DEN2015 IN2015DN03984A (he) 2012-11-21 2013-11-21

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
IN3984DEN2015 IN2015DN03984A (he) 2012-11-21 2013-11-21
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
IN2015DN03984A true IN2015DN03984A (he) 2015-10-02

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3984DEN2015 IN2015DN03984A (he) 2012-11-21 2013-11-21

Country Status (18)

Country Link
EP (1) EP2922525A1 (he)
JP (1) JP2016500088A (he)
KR (1) KR20150085826A (he)
CN (1) CN104797240A (he)
AR (1) AR093585A1 (he)
AU (1) AU2013349682A1 (he)
BR (1) BR112015011430A2 (he)
CA (1) CA2891365A1 (he)
EA (1) EA201590805A1 (he)
HK (1) HK1213779A1 (he)
IL (1) IL238648A0 (he)
IN (1) IN2015DN03984A (he)
MX (1) MX2015006399A (he)
PH (1) PH12015501096A1 (he)
SG (2) SG11201503913TA (he)
TW (1) TW201422254A (he)
WO (1) WO2014079922A1 (he)
ZA (1) ZA201503603B (he)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210103589A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
WO2016081772A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
EP3244881A4 (en) 2015-01-12 2018-08-15 Nano Pharmaceutical Laboratories LLC Layered sustained-release microbeads and methods of making the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2018111400A (ru) * 2015-09-01 2019-10-03 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Препарат пролонгированного, отсроченного и немедленного высвобождения, способ его получения и применения
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
AU2016331871A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
RU2018126368A (ru) * 2015-12-18 2020-01-20 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиция для уменьшения частоты мочеиспускания, способ ее получения и применение
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3046725A1 (en) * 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4052997A (en) 1996-07-19 1998-02-10 Clarke-Garegg, Margaret A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
DE60307082T4 (de) * 2002-05-07 2015-04-30 Ferring B.V. In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (zh) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
CA2769760A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
PL2552418T3 (pl) * 2010-03-29 2017-12-29 Ferring B.V. Szybko rozpuszczająca się kompozycja farmaceutyczna
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
MX2015006399A (es) 2015-07-21
EA201590805A1 (ru) 2015-11-30
AR093585A1 (es) 2015-06-10
HK1213779A1 (zh) 2016-07-15
EP2922525A1 (en) 2015-09-30
IL238648A0 (he) 2015-06-30
SG11201503913TA (en) 2015-06-29
AU2013349682A1 (en) 2015-06-04
CA2891365A1 (en) 2014-05-30
JP2016500088A (ja) 2016-01-07
BR112015011430A2 (pt) 2017-07-11
CN104797240A (zh) 2015-07-22
SG10201703388TA (en) 2017-05-30
KR20150085826A (ko) 2015-07-24
PH12015501096A1 (en) 2015-07-27
ZA201503603B (en) 2016-01-27
TW201422254A (zh) 2014-06-16
WO2014079922A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
PH12015501096A1 (en) Composition for immediate and extended release
HK1219432A1 (zh) 以嘧啶化合物爲有效成分的醫藥組合物
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
IL238713A0 (he) שחרור רכיב רוקחי פעיל בוויסות עצמי
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EP3082817A4 (en) Compositions for drug administration
EP2849770A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE DISPOSAL OF ESSENTIALLY WATER-INSOLICED MEDICINAL PRODUCTS
HK1223583A1 (zh) 透皮釋放活性物質的系統
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
IL232973B (he) תכשירי רוקחות המכילים מיצלות המכילים קומפלקס קלטורי לשחרור תרופה מבקר ושימושים בהם
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
ZA201504967B (en) Transdermal dosage form for low-melting point active agent
MX2016001422A (es) Composicion farmaceutica de fingolimod.
IL240666A0 (he) תכשירי רוקחות למתן דרך הפה ושימושים בהם
HK1208188A1 (en) Formulations for the delivery of active ingredients
IL236466B (he) הרכב תרופתי לשחרור של רכיבים פעילים
ZA201505084B (en) Monolithic dosage form for the modified release of an active ingredient combination
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
HUE049663T2 (hu) Gyógyszerbejuttató rendszer egy vagy több aktív összetevõhöz
PT2953617T (pt) Composições farmacêuticas que incorporam fármacos de baixa dose
MX2012014969A (es) Composiciones farmaceuticas estables de amlodipina con telmisartan.
MX2015013279A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
IN2013CH02437A (he)
GB201300437D0 (en) Injectable Active Ingredient Release Compositions and Methods for Their Production and Use